Liposomal nanostructures for photosensitizer delivery

Lasers in Surgery and Medicine

Volumn 43, Issue 7, 2011, Pages 734-748

  Jin, Cheng S ^a,b   Zheng, Gang ^a,b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

liposome; nanoparticle; photodynamic therapy; porphysomes

Indexed keywords

1,1' DIOCTADECYL 3,3,3',3' TETRAMETHYLINDOCARBOCYANINE; APTAMER; ARCHAEOSOME; BACTERIOCHLOROPHYLL A; DIOLEOYLPHOSPHATIDYLETHANOLAMINE; DIPALMITOYLPHOSPHATIDYLCHOLINE; DOXORUBICIN; ETHOSOME; FLUORESCEIN ISOTHIOCYANATE; FOLIC ACID; FOSLIP; FOSPEG; GELATINASE B; HYPERICIN; INVASOME; LIPOSOME; MACROGOL; MONOCLONAL ANTIBODY KI 67; MONOSIALOGANGLIOSIDE; NANOCELL; NANOMATERIAL; NANOPARTICLE; NIOSOME; PENTAPEPTIDE; PHOSPHOLIPASE A2; PORPHYSOME; TEMOPORFIN; TETRASULFOPHTHALOCYANINE ALUMINUM; TRANSFERRIN; TRANSFERSOME; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERTEPORFIN; VIROSOME;

DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG TARGETING; ENCAPSULATION; ENDOCYTOSIS; HUMAN; HYDROPHILICITY; HYDROPHOBICITY; MYOPIA; NONHUMAN; OCULAR HISTOPLASMOSIS; PARTICLE SIZE; PHOTODYNAMIC THERAPY; PHOTOTRANSDUCTION; PRIORITY JOURNAL; REVIEW; SUBRETINAL NEOVASCULARIZATION; ULTRASOUND;

DRUG CARRIERS; HUMANS; LIPOSOMES; MOLECULAR TARGETED THERAPY; NANOPARTICLES; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS;

EID: 80052057080     PISSN: 01968092     EISSN: 10969101     Source Type: Journal    
DOI: 10.1002/lsm.21101     Document Type: Review

References (163)

1. MacDonald IJ, Dougherty DJ,. Basic principles of photodynamic therapy. J Porphyr Phthalocyanines 2001; 5 (2): 105-129. (Pubitemid 32125231)
2. Foote CS,. Mechanisms of photooxygenation. Prog Clin Biol Res 1984; 170: 3-18.
3. Kessel D,. Delivery of photosensitizing agents. Adv Drug Deliv Rev 2004; 56 (1): 7-8. (Pubitemid 38045420)
4. Dougherty TJ, Gomer CJ, Henderson BW, Jori G, Kessel D, Korbelik M, Moan J, Peng Q,. Photodynamic therapy. J Natl Cancer Inst 1998; 90 (12): 889-905. (Pubitemid 28304157)
5. Wilson BC, Patterson MS,. The physics, biophysics and technology of photodynamic therapy. Phys Med Biol 2008; 53 (9): R61-R109. (Pubitemid 351570924)
6. Gomer CJ,. What makes a good photosensitizer for photodynamic therapy? J Photochem Photobiol B 1988; 1 (3): 376-378.
7. Pervaiz S, Olivo M,. Art and science of photodynamic therapy. Clin Exp Pharmacol Physiol 2006; 33 (5-6): 551-556.
8. Allison RR, Sibata CH,. Oncologic photodynamic therapy photosensitizers: A clinical review. Photodiagnosis Photodyn Ther 2010; 7 (2): 61-75.
9. O'Connor AE, Gallagher WM, Byrne AT,. Porphyrin and nonporphyrin photosensitizers in oncology: Preclinical and clinical advances in photodynamic therapy. Photochem Photobiol 2009; 85 (5): 1053-1074.
10. Chen B, Pogue BW, Hasan T,. Liposomal delivery of photosensitising agents. Expert Opin Drug Deliv 2005; 2 (3): 477-487. (Pubitemid 41683223)
11. Konan YN, Gurny R, Allemann E,. State of the art in the delivery of photosensitizers for photodynamic therapy. J Photochem Photobiol B 2002; 66 (2): 89-106. (Pubitemid 34240266)
12. Allemann E, Brasseur N, Kudrevich SV, La Madeleine C, van Lier JE,. Photodynamic activities and biodistribution of fluorinated zinc phthalocyanine derivatives in the murine EMT-6 tumour model. Int J Cancer 1997; 72 (2): 289-294. (Pubitemid 27314887)
13. De Rosa FS, Marchetti JM, Thomazini JA, Tedesco AC, Bentley MV,. A vehicle for photodynamic therapy of skin cancer: Influence of dimethylsulphoxide on 5-aminolevulinic acid in vitro cutaneous permeation and in vivo protoporphyrin IX accumulation determined by confocal microscopy. J Control Release 2000; 65 (3): 359-366. (Pubitemid 30122938)
14. Araujo LM, Thomazine JA, Lopez RF,. Development of microemulsions to topically deliver 5-aminolevulinic acid in photodynamic therapy. Eur J Pharm Biopharm 2010; 75 (1): 48-55.
15. Camerin M, Magaraggia M, Soncin M, Jori G, Moreno M, Chambrier I, Cook MJ, Russell DA,. The in vivo efficacy of phthalocyanine-nanoparticle conjugates for the photodynamic therapy of amelanotic melanoma. Eur J Cancer 2010; 46 (10): 1910-1918.
16. van Nostrum CF,. Polymeric micelles to deliver photosensitizers for photodynamic therapy. Adv Drug Deliv Rev 2004; 56 (1): 9-16. (Pubitemid 38045421)
17. Hofman JW, Carstens MG, van Zeeland F, Helwig C, Flesch FM, Hennink WE, van Nostrum CF,. Photocytotoxicity of mTHPC (temoporfin) loaded polymeric micelles mediated by lipase catalyzed degradation. Pharm Res 2008; 25 (9): 2065-2073.
18. Tsai T, Yang YT, Wang TH, Chien HF, Chen CT,. Improved photodynamic inactivation of gram-positive bacteria using hematoporphyrin encapsulated in liposomes and micelles. Lasers Surg Med 2009; 41 (4): 316-322.
19. Elbayoumi TA, Pabba S, Roby A, Torchilin VP,. Antinucleosome antibody-modified liposomes and lipid-core micelles for tumor-targeted delivery of therapeutic and diagnostic agents. J Liposome Res 2007; 17 (1): 1-14. (Pubitemid 46631140)
20. Derycke AS, de Witte PA,. Liposomes for photodynamic therapy. Adv Drug Deliv Rev 2004; 56 (1): 17-30. (Pubitemid 38045422)
21. Song L, Li H, Sunar U, Chen J, Corbin I, Yodh AG, Zheng G,. Naphthalocyanine-reconstituted LDL nanoparticles for in vivo cancer imaging and treatment. Int J Nanomed 2007; 2 (4): 767-774.
22. Zheng G, Li H, Zhang M, Lund-Katz S, Chance B, Glickson JD,. Low-density lipoprotein reconstituted by pyropheophorbide cholesteryl oleate as target-specific photosensitizer. Bioconjug Chem 2002; 13 (3): 392-396. (Pubitemid 34527499)
23. Cao W, Ng KK, Corbin I, Zhang Z, Ding L, Chen J, Zheng G,. Synthesis and evaluation of a stable bacteriochlorophyll-analog and its incorporation into high-density lipoprotein nanoparticles for tumor imaging. Bioconjug Chem 2009; 20 (11): 2023-2031.
24. Zheng G, Chen J, Li H, Glickson JD,. Rerouting lipoprotein nanoparticles to selected alternate receptors for the targeted delivery of cancer diagnostic and therapeutic agents. Proc Natl Acad Sci USA 2005; 102 (49): 17757-17762. (Pubitemid 41803570)
25. Li H, Marotta DE, Kim S, Busch TM, Wileyto EP, Zheng G,. High payload delivery of optical imaging and photodynamic therapy agents to tumors using phthalocyanine-reconstituted low-density lipoprotein nanoparticles. J Biomed Opt 2005; 10 (4): 41203.
26. Bechet D, Couleaud P, Frochot C, Viriot ML, Guillemin F, Barberi-Heyob M,. Nanoparticles as vehicles for delivery of photodynamic therapy agents. Trends Biotechnol 2008; 26 (11): 612-66621.
27. Mezei M, Gulasekharam V,. Liposomes-A selective drug delivery system for the topical route of administration. Lotion dosage form. Life Sci 1980; 26 (18): 1473-1477. (Pubitemid 10042852)
28. Mezei M, Gulasekharam V,. Liposomes-A selective drug delivery system for the topical route of administration: Gel dosage form. J Pharm Pharmacol 1982; 34 (7): 473-474. (Pubitemid 12082555)
29. Postigo F, Mora M, De Madariaga MA, Nonell S, Sagrista ML,. Incorporation of hydrophobic porphyrins into liposomes: Characterization and structural requirements. Int J Pharm 2004; 278 (2): 239-254. (Pubitemid 38759497)
30. Garcia AM, Alarcon E, Munoz M, Scaiano JC, Edwards AM, Lissi E,. Photophysical behaviour and photodynamic activity of zinc phthalocyanines associated to liposomes. Photochem Photobiol Sci 2011. 10: 507-514.
31. Kosobe T, Moriyama E, Tokuoka Y, Kawashima N,. Size and surface charge effect of 5-aminolevulinic acid-containing liposomes on photodynamic therapy for cultivated cancer cells. Drug Dev Ind Pharm 2005; 31 (7): 623-629. (Pubitemid 41356204)
32. Nisnevitch M, Nakonechny F, Nitzan Y,. Photodynamic antimicrobial chemotherapy by liposome-encapsulated water-soluble photosensitizers. Bioorg Khim 2010; 36 (3): 396-402.
33. Drummond DC, Meyer O, Hong K, Kirpotin DB, Papahadjopoulos D,. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev 1999; 51 (4): 691-743.
34. An JS, Kim JE, Lee DH, Kim BY, Cho S, Kwon IH, Choi WW, Kang SM, Won CH, Chang SE, Lee MW, Choi JH, Moon KC,. 0.5% Liposome-encapsulated 5-aminolevulinic acid (ALA) photodynamic therapy for acne treatment. J Cosmet Laser Ther 2011; 13 (1): 28-32.
35. Gabizon A, Papahadjopoulos D,. The role of surface charge and hydrophilic groups on liposome clearance in vivo. Biochim Biophys Acta 1992; 1103 (1): 94-100.
36. Yamaguchi T, Nomura M, Matsuoka T, Koda S,. Effects of frequency and power of ultrasound on the size reduction of liposome. Chem Phys Lipids 2009; 160 (1): 58-62.
37. Woodbury DJ, Richardson ES, Grigg AW, Welling RD, Knudson BH,. Reducing liposome size with ultrasound: Bimodal size distributions. J Liposome Res 2006; 16 (1): 57-80.
38. Jesorka A, Orwar O,. Liposomes: Technologies and analytical applications. Annu Rev Anal Chem (Palo Alto Calif) 2008; 1: 801-832.
39. Berger N, Sachse A, Bender J, Schubert R, Brandl M,. Filter extrusion of liposomes using different devices: Comparison of liposome size, encapsulation efficiency, and process characteristics. Int J Pharm 2001; 223 (1-2): 55-68. (Pubitemid 32640878)
40. Olson F, Hunt CA, Szoka FC, Vail WJ, Papahadjopoulos D,. Preparation of liposomes of defined size distribution by extrusion through polycarbonate membranes. Biochim Biophys Acta 1979; 557 (1): 9-23. (Pubitemid 10245657)
41. Lapinski MM, Castro-Forero A, Greiner AJ, Ofoli RY, Blanchard GJ,. Comparison of liposomes formed by sonication and extrusion: Rotational and translational diffusion of an embedded chromophore. Langmuir 2007; 23 (23): 11677-11683. (Pubitemid 350133015)
42. Pierre MB, Tedesco AC, Marchetti JM, Bentley MV,. Stratum corneum lipids liposomes for the topical delivery of 5-aminolevulinic acid in photodynamic therapy of skin cancer: Preparation and in vitro permeation study. BMC Dermatol 2001; 1: 5.
43. Verma DD, Verma S, Blume G, Fahr A,. Particle size of liposomes influences dermal delivery of substances into skin. Int J Pharm 2003; 258 (1-2): 141-151. (Pubitemid 36712878)
44. Nagayasu A, Uchiyama K, Kiwada H,. The size of liposomes: A factor which affects their targeting efficiency to tumors and therapeutic activity of liposomal antitumor drugs. Adv Drug Deliv Rev 1999; 40 (1-2): 75-87. (Pubitemid 29486605)
45. Abra RM, Hunt CA,. Liposome disposition in vivo. III. Dose and vesicle-size effects. Biochim Biophys Acta 1981; 666 (3): 493-503. (Pubitemid 12144883)
46. Senior JH,. Fate and behavior of liposomes in vivo: A review of controlling factors. Crit Rev Ther Drug Carrier Syst 1987; 3 (2): 123-193. (Pubitemid 17219201)
47. Gabizon AA, Shmeeda H, Zalipsky S,. Pros and cons of the liposome platform in cancer drug targeting. J Liposome Res 2006; 16 (3): 175-183. (Pubitemid 44358991)
48. Yuan F, Dellian M, Fukumura D, Leunig M, Berk DA, Torchilin VP, Jain RK,. Vascular permeability in a human tumor xenograft: Molecular size dependence and cutoff size. Cancer Res 1995; 55 (17): 3752-3756.
49. Charrois GJ, Allen TM,. Rate of biodistribution of STEALTH liposomes to tumor and skin: Influence of liposome diameter and implications for toxicity and therapeutic activity. Biochim Biophys Acta 2003; 1609 (1): 102-108. (Pubitemid 36044071)
50. Liu D, Huang L,. Size homogeneity of a liposome preparation is crucial for liposome biodistribution in vivo. J Liposome Res 1992; 2 (1): 57-66.
51. Senior J, Gregoriadis G,. Stability of small unilamellar liposomes in serum and clearance from the circulation: The effect of the phospholipid and cholesterol components. Life Sci 1982; 30 (24): 2123-2136. (Pubitemid 12066826)
52. Gabizon A, Price DC, Huberty J, Bresalier RS, Papahadjopoulos D,. Effect of liposome composition and other factors on the targeting of liposomes to experimental tumors: Biodistribution and imaging studies. Cancer Res 1990; 50 (19): 6371-6378. (Pubitemid 20323703)
53. Papahadjopoulos D, Allen TM, Gabizon A, Mayhew E, Matthay K, Huang SK, Lee KD, Woodle MC, Lasic DD, Redemann C, Sterically stabilized liposomes: Improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci USA 1991; 88 (24): 11460-11464. (Pubitemid 21916061)
54. Patel HM, Tuzel NS, Ryman BE,. Inhibitory effect of cholesterol on the uptake of liposomes by liver and spleen. Biochim Biophys Acta 1983; 761 (2): 142-151. (Pubitemid 14214793)
55. Allen TM,. A study of phospholipid interactions between high-density lipoproteins and small unilamellar vesicles. Biochim Biophys Acta 1981; 640 (2): 385-397.
56. Raz A, Bucana C, Fogler WE, Poste G, Fidler IJ,. Biochemical, morphological, and ultrastructural studies on the uptake of liposomes by murine macrophages. Cancer Res 1981; 41 (2): 487-494. (Pubitemid 11179386)
57. Jones MN,. The surface properties of phospholipid liposome systems and their characterisation. Adv Colloid Interface Sci 1995; 54: 93-128.
58. Popov M, Linder C, Deckelbaum RJ, Grinberg S, Hansen IH, Shaubi E, Waner T, Heldman E,. Cationic vesicles from novel bolaamphiphilic compounds. J Liposome Res 2010; 20 (2): 147-159.
59. Liu D, Mori A, Huang L,. Role of liposome size and RES blockade in controlling biodistribution and tumor uptake of GM1-containing liposomes. Biochim Biophys Acta 1992; 1104 (1): 95-101.
60. Chonn A, Semple SC, Cullis PR,. Association of blood proteins with large unilamellar liposomes in vivo. Relation to circulation lifetimes. J Biol Chem 1992; 267 (26): 18759-18765.
61. Litzinger DC, Buiting AM, van Rooijen N, Huang L,. Effect of liposome size on the circulation time and intraorgan distribution of amphipathic poly(ethylene glycol)-containing liposomes. Biochim Biophys Acta 1994; 1190 (1): 99-107. (Pubitemid 24066264)
62. Harris JM, Chess RB,. Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov 2003; 2 (3): 214-221. (Pubitemid 37361666)
63. Bressler NM, Bressler SB,. Photodynamic therapy with verteporfin (Visudyne): Impact on ophthalmology and visual sciences. Invest Ophthalmol Vis Sci 2000; 41 (3): 624-628. (Pubitemid 30158868)
64. Ichikawa K, Hikita T, Maeda N, Yonezawa S, Takeuchi Y, Asai T, Namba Y, Oku N,. Antiangiogenic photodynamic therapy (PDT) by using long-circulating liposomes modified with peptide specific to angiogenic vessels. Biochim Biophys Acta 2005; 1669 (1): 69-74. (Pubitemid 40544523)
65. Buchholz J, Kaser-Hotz B, Khan T, Rohrer Bley C, Melzer K, Schwendener RA, Roos M, Walt H,. Optimizing photodynamic therapy: In vivo pharmacokinetics of liposomal meta-(tetrahydroxyphenyl)chlorin in feline squamous cell carcinoma. Clin Cancer Res 2005; 11 (20): 7538-7544. (Pubitemid 41507716)
66. Pegaz B, Debefve E, Ballini JP, Wagnieres G, Spaniol S, Albrecht V, Scheglmann DV, Nifantiev NE, van den Bergh H, Konan-Kouakou YN,. Photothrombic activity of m-THPC-loaded liposomal formulations: Pre-clinical assessment on chick chorioallantoic membrane model. Eur J Pharm Sci 2006; 28 (1-2): 134-140.
67. Gabizon A,. Liposome circulation time and tumor targeting: Implications for cancer chemotherapy. Adv Drug Deliv Rev 1995; 16 (2-3): 285-294.
68. Matsumura Y, Maeda H,. A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986; 46 (12 Pt 1): 6387-6392. (Pubitemid 17221789)
69. Oku N, Ishii T,. Antiangiogenic photodynamic therapy with targeted liposomes. Methods Enzymol 2009; 465: 313-330.
70. Wang M, Thanou M,. Targeting nanoparticles to cancer. Pharmacol Res 2010; 62 (2): 90-99.
71. Miller CR, Bondurant B, McLean SD, McGovern KA, O'Brien DF,. Liposome-cell interactions in vitro: Effect of liposome surface charge on the binding and endocytosis of conventional and sterically stabilized liposomes. Biochemistry 1998; 37 (37): 12875-12883. (Pubitemid 28433520)
72. Torchilin VP,. Passive and active drug targeting: Drug delivery to tumors as an example. Handb Exp Pharmacol 2010; 197 (part 1): 3-53.
73. Yemul S, Berger C, Estabrook A, Suarez S, Edelson R, Bayley H,. Selective killing of T lymphocytes by phototoxic liposomes. Proc Natl Acad Sci USA 1987; 84 (1): 246-250. (Pubitemid 17013611)
74. Bergstrom LC, Vucenik I, Hagen IK, Chernomorsky SA, Poretz RD,. In-vitro photocytotoxicity of lysosomotropic immunoliposomes containing pheophorbide a with human bladder carcinoma cells. J Photochem Photobiol B 1994; 24 (1): 17-23.
75. Morgan J, Lottman H, Abbou CC, Chopin DK,. A comparison of direct and liposomal antibody conjugates of sulfonated aluminum phthalocyanines for selective photoimmunotherapy of human bladder carcinoma. Photochem Photobiol 1994; 60 (5): 486-496. (Pubitemid 2161915)
76. Rahmanzadeh R, Rai P, Celli JP, Rizvi I, Baron-Luhr B, Gerdes J, Hasan T,. Ki-67 as a molecular target for therapy in an in vitro three-dimensional model for ovarian cancer. Cancer Res 2010; 70 (22): 9234-9242.
77. Sofou S, Sgouros G,. Antibody-targeted liposomes in cancer therapy and imaging. Expert Opin Drug Deliv 2008; 5 (2): 189-204. (Pubitemid 351308311)
78. Derycke AS, De Witte PA,. Transferrin-mediated targeting of hypericin embedded in sterically stabilized PEG-liposomes. Int J Oncol 2002; 20 (1): 181-187.
79. Gijsens A, Derycke A, Missiaen L, De Vos D, Huwyler J, Eberle A, de Witte P,. Targeting of the photocytotoxic compound AlPcS4 to Hela cells by transferrin conjugated PEG-liposomes. Int J Cancer 2002; 101 (1): 78-85. (Pubitemid 34833001)
80. Derycke AS, Kamuhabwa A, Gijsens A, Roskams T, De Vos D, Kasran A, Huwyler J, Missiaen L, de Witte PA,. Transferrin-conjugated liposome targeting of photosensitizer AlPcS4 to rat bladder carcinoma cells. J Natl Cancer Inst 2004; 96 (21): 1620-1630. (Pubitemid 39534886)
81. Hilgenbrink AR, Low PS,. Folate receptor-mediated drug targeting: From therapeutics to diagnostics. J Pharm Sci 2005; 94 (10): 2135-2146. (Pubitemid 41665275)
82. Lee RJ, Low PS,. Delivery of liposomes into cultured KB cells via folate receptor-mediated endocytosis. J Biol Chem 1994; 269 (5): 3198-3204. (Pubitemid 24237629)
83. Lee RJ, Wang S, Low PS,. Measurement of endosome pH following folate receptor-mediated endocytosis. Biochim Biophys Acta 1996; 1312 (3): 237-242. (Pubitemid 26246522)
84. Yang J, Chen H, Vlahov IR, Cheng JX, Low PS,. Characterization of the pH of folate receptor-containing endosomes and the rate of hydrolysis of internalized acid-labile folate-drug conjugates. J Pharmacol Exp Ther 2007; 321 (2): 462-468. (Pubitemid 46624512)
85. Qualls MM, Thompson DH,. Chloroaluminum phthalocyanine tetrasulfonate delivered via acid-labile diplasmenylcholine-folate liposomes: Intracellular localization and synergistic phototoxicity. Int J Cancer 2001; 93 (3): 384-392. (Pubitemid 32592058)
86. Garcia-Diaz M, Nonell S, Villanueva A, Stockert JC, Canete M, Casado A, Mora M, Sagrista ML,. Do folate-receptor targeted liposomal photosensitizers enhance photodynamic therapy selectivity? Biochim Biophys Acta 2011. 1808 (4): 1063-1071.
87. Paulos CM, Reddy JA, Leamon CP, Turk MJ, Low PS,. Ligand binding and kinetics of folate receptor recycling in vivo: Impact on receptor-mediated drug delivery. Mol Pharmacol 2004; 66 (6): 1406-1414. (Pubitemid 39564767)
88. Israeli RS, Powell CT, Corr JG, Fair WR, Heston WD,. Expression of the prostate-specific membrane antigen. Cancer Res 1994; 54 (7): 1807-1811. (Pubitemid 24116191)
89. Bander NH, Nanus DM, Milowsky MI, Kostakoglu L, Vallabahajosula S, Goldsmith SJ,. Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen. Semin Oncol 2003; 30 (5): 667-676.
90. Liu T, Wu LY, Kazak M, Berkman CE,. Cell-Surface labeling and internalization by a fluorescent inhibitor of prostate-specific membrane antigen. Prostate 2008; 68 (9): 955-964. (Pubitemid 351794160)
91. Liu T, Wu LY, Choi JK, Berkman CE,. Targeted photodynamic therapy for prostate cancer: Inducing apoptosis via activation of the caspase-8/-3 cascade pathway. Int J Oncol 2010; 36 (4): 777-784.
92. Liu T, Wu LY, Berkman CE,. Prostate-specific membrane antigen-targeted photodynamic therapy induces rapid cytoskeletal disruption. Cancer Lett 2010; 296 (1): 106-112.
93. Dhar S, Kolishetti N, Lippard SJ, Farokhzad OC,. Targeted delivery of a cisplatin prodrug for safer and more effective prostate cancer therapy in vivo. Proc Natl Acad Sci USA 2011; 108 (5): 1850-1855.
94. Zhou J, Rossi JJ,. Cell-specific aptamer-mediated targeted drug delivery. Oligonucleotides 2011; 21 (1): 1-10.
95. Medley CD, Bamrungsap S, Tan W, Smith JE,. Aptamer-conjugated nanoparticles for cancer cell detection. Anal Chem 2011; 83 (3): 727-734.
96. Tuerk C, Gold L,. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 1990; 249 (4968): 505-510.
97. Mallikaratchy P, Tang Z, Tan W,. Cell specific aptamer-photosensitizer conjugates as a molecular tool in photodynamic therapy. ChemMed Chem 2008; 3 (3): 425-428.
98. Ferreira CS, Cheung MC, Missailidis S, Bisland S, Gariepy J,. Phototoxic aptamers selectively enter and kill epithelial cancer cells. Nucleic Acids Res 2009; 37 (3): 866-876.
99. Shieh YA, Yang SJ, Wei MF, Shieh MJ,. Aptamer-based tumor-targeted drug delivery for photodynamic therapy. ACS Nano 2010; 4 (3): 1433-1442.
100. Cao Z, Tong R, Mishra A, Xu W, Wong GC, Cheng J, Lu Y,. Reversible cell-specific drug delivery with aptamer-functionalized liposomes. Angew Chem Int Ed Engl 2009; 48 (35): 6494-6498.
101. Kang H, O'Donoghue MB, Liu H, Tan W,. A liposome-based nanostructure for aptamer directed delivery. Chem Commun (Camb) 2010; 46 (2): 249-251.
102. Drummond DC, Noble CO, Hayes ME, Park JW, Kirpotin DB,. Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier development. J Pharm Sci 2008; 97 (11): 4696-4740.
103. Yavlovich A, Smith B, Gupta K, Blumenthal R, Puri A,. Light-sensitive lipid-based nanoparticles for drug delivery: Design principles and future considerations for biological applications. Mol Membr Biol 2010; 27 (7): 364-381.
104. Guo X, Szoka FC, Jr., Chemical approaches to triggerable lipid vesicles for drug and gene delivery. Acc Chem Res 2003; 36 (5): 335-341.
105. Torchilin V,. Multifunctional stimuli-sensitive pharmaceutical nanocarriers. Eur J Pharm Biopharm 2009; 71 (3): 431-444.
106. Simoes S, Moreira JN, Fonseca C, Duzgunes N, de Lima MC,. On the formulation of pH-sensitive liposomes with long circulation times. Adv Drug Deliv Rev 2004; 56 (7): 947-965. (Pubitemid 38520203)
107. Anderson VC, Thompson DH,. Triggered release of hydrophilic agents from plasmalogen liposomes using visible light or acid. Biochim Biophys Acta 1992; 1109 (1): 33-42.
108. Monkkonen J, Urtti A,. Lipid fusion in oligonucleotide and gene delivery with cationic lipids. Adv Drug Deliv Rev 1998; 34 (1): 37-49. (Pubitemid 28464477)
109. Galdiero S, Falanga A, Vitiello M, Browne H, Pedone C, Galdiero M,. Fusogenic domains in herpes simplex virus type 1 glycoprotein H. J Biol Chem 2005; 280 (31): 28632-28643. (Pubitemid 41105764)
110. Tu Y, Kim JS,. A fusogenic segment of glycoprotein H from herpes simplex virus enhances transfection efficiency of cationic liposomes. J Gene Med 2008; 10 (6): 646-654. (Pubitemid 351936537)
111. Wang X, Yang L, Chen ZG, Shin DM,. Application of nanotechnology in cancer therapy and imaging. CA Cancer J Clin 2008; 58 (2): 97-110. (Pubitemid 351521865)
112. Vihinen P, Ala-aho R, Kahari VM,. Matrix metalloproteinases as therapeutic targets in cancer. Curr Cancer Drug Targets 2005; 5 (3): 203-220. (Pubitemid 40694861)
113. Leslie CC,. Properties and regulation of cytosolic phospholipase A2. J Biol Chem 1997; 272 (27): 16709-16712.
114. Andresen TL, Thompson DH, Kaasgaard T,. Enzyme-triggered nanomedicine: Drug release strategies in cancer therapy. Mol Membr Biol 2010; 27 (7): 353-363.
115. Sarkar N, Banerjee J, Hanson AJ, Elegbede AI, Rosendahl T, Krueger AB, Banerjee AL, Tobwala S, Wang R, Lu X, Mallik S, Srivastava DK,. Matrix metalloproteinase-assisted triggered release of liposomal contents. Bioconjug Chem 2008; 19 (1): 57-64. (Pubitemid 351213835)
116. Shum P, Kim JM, Thompson DH,. Phototriggering of liposomal drug delivery systems. Adv Drug Deliv Rev 2001; 53 (3): 273-284. (Pubitemid 34024910)
117. Regen SL, Singh A, Oehme G, Singh M,. Polymerized phosphatidyl choline vesicles. Stabilized and controllable time-release carriers. Biochem Biophys Res Commun 1981; 101 (1): 131-136.
118. Morgan CG, Bisby RH, Johnson SA, Mitchell AC,. Fast solute release from photosensitive liposomes: An alternative to 'caged' reagents for use in biological systems. FEBS Lett 1995; 375 (1-2): 113-116.
119. Chandra B, Mallik S, Srivastava DK,. Design of photocleavable lipids and their application in liposomal "uncorking ". Chem Commun (Camb) 2005; 2005 (24): 3021-3023. (Pubitemid 40956696)
120. Thompson DH, Gerasimov OV, Wheeler JJ, Rui Y, Anderson VC,. Triggerable plasmalogen liposomes: Improvement of system efficiency. Biochim Biophys Acta 1996; 1279 (1): 25-34. (Pubitemid 26067413)
121. Karino T, Koga S, Maeta M,. Experimental studies of the effects of local hyperthermia on blood flow, oxygen pressure and pH in tumors. Jpn J Surg 1988; 18 (3): 276-283.
122. Blok MC, van der Neut-Kok EC, van Deenen LL, de Gier J,. The effect of chain length and lipid phase transitions on the selective permeability properties of liposomes. Biochim Biophys Acta 1975; 406 (2): 187-196.
123. Yatvin MB, Weinstein JN, Dennis WH, Blumenthal R,. Design of liposomes for enhanced local release of drugs by hyperthermia. Science 1978; 202 (4374): 1290-1293. (Pubitemid 9154441)
124. Koning GA, Eggermont AM, Lindner LH, ten Hagen TL,. Hyperthermia and thermosensitive liposomes for improved delivery of chemotherapeutic drugs to solid tumors. Pharm Res 2010; 27 (8): 1750-1754.
125. Negussie AH, Miller JL, Reddy G, Drake SK, Wood BJ, Dreher MR,. Synthesis and in vitro evaluation of cyclic NGR peptide targeted thermally sensitive liposome. J Control Release 2010; 143 (2): 265-273.
126. Evjen TJ, Nilssen EA, Barnert S, Schubert R, Brandl M, Fossheim SL,. Ultrasound-mediated destabilization and drug release from liposomes comprising dioleoylphosphatidylethanolamine. Eur J Pharm Sci 2011; 42 (4): 380-386.
127. Huang SL, MacDonald RC,. Acoustically active liposomes for drug encapsulation and ultrasound-triggered release. Biochim Biophys Acta 2004; 1665 (1-2): 134-141. (Pubitemid 39303578)
128. Takeuchi Y, Ichikawa K, Yonezawa S, Kurohane K, Koishi T, Nango M, Namba Y, Oku N,. Intracellular target for photosensitization in cancer antiangiogenic photodynamic therapy mediated by polycation liposome. J Control Release 2004; 97 (2): 231-240. (Pubitemid 38759480)
129. Berg K, Moan J,. Lysosomes as photochemical targets. Int J Cancer 1994; 59: 814-822.
130. Bohmer RM, Morstyn G,. Uptake of hematoporphyrin derivative by normal and malignant cells: Effect of serum, pH, temperature, and cell size. Cancer Res 1985; 45 (11 Pt 1): 5328-5334. (Pubitemid 16200840)
131. Woodburn KW, Vardaxis NJ, Hill JS, Kaye AH, Phillips DR,. Subcellular localization of porphyrins using confocal laser scanning microscopy. Photochem Photobiol 1991; 54 (5): 725-732.
132. Hamblin MR, Miller JL, Ortel B,. Scavenger-receptor targeted photodynamic therapy. Photochem Photobiol 2000; 72 (4): 533-540.
133. Fukuda H, Paredes S, Batlle AM,. Tumour-localizing properties of porphyrins. In vivo studies using free and liposome encapsulated aminolevulinic acid. Comp Biochem Physiol B 1992; 102 (2): 433-436.
134. Ricchelli F, Gobbo S, Jori G, Moreno G, Vinzens F, Salet C,. Photosensitization of mitochondria by liposome-bound porphyrins. Photochem Photobiol 1993; 58 (1): 53-58.
135. Liu W, Jensen TJ, Fronczek FR, Hammer RP, Smith KM, Vicente MG,. Synthesis and cellular studies of nonaggregated water-soluble phthalocyanines. J Med Chem 2005; 48 (4): 1033-1041. (Pubitemid 40270447)
136. Handjani-Vila RM, Ribier A, Rondot B, Vanlerberghie G,. Dispersions of lamellar phases of non-ionic lipids in cosmetic products. Int J Cosmet Sci 1979; 1 (5): 303-314. (Pubitemid 10125800)
137. Uchegbu IF, Vyas SP,. Non-ionic surfactant based vesicles (niosomes) in drug delivery. Int J Pharm 1998; 172: 33-70. (Pubitemid 28430243)
138. Azmin MN, Florence AT, Handjani-Vila RM, Stuart JF, Vanlerberghe G, Whittaker JS,. The effect of non-ionic surfactant vesicle (niosome) entrapment on the absorption and distribution of methotrexate in mice. J Pharm Pharmacol 1985; 37 (4): 237-242. (Pubitemid 15149834)
139. Azeem A, Anwer MK, Talegaonkar S,. Niosomes in sustained and targeted drug delivery: Some recent advances. J Drug Target 2009; 17 (9): 671-689.
140. Cevc G, Gebauer D, Stieber J, Schatzlein A, Blume G,. Ultraflexible vesicles, Transfersomes, have an extremely low pore penetration resistance and transport therapeutic amounts of insulin across the intact mammalian skin. Biochim Biophys Acta 1998; 1368 (2): 201-215. (Pubitemid 28031874)
141. Cevc G, Schatzlein A, Richardsen H,. Ultradeformable lipid vesicles can penetrate the skin and other semi-permeable barriers unfragmented. Evidence from double label CLSM experiments and direct size measurements. Biochim Biophys Acta 2002; 1564 (1): 21-30. (Pubitemid 34717865)
142. Rother M, Lavins BJ, Kneer W, Lehnhardt K, Seidel EJ, Mazgareanu S,. Efficacy and safety of epicutaneous ketoprofen in Transfersome (IDEA-033) versus oral celecoxib and placebo in osteoarthritis of the knee: Multicentre randomised controlled trial. Ann Rheum Dis 2007; 66 (9): 1178-1183. (Pubitemid 47309734)
143. Fesq H, Lehmann J, Kontny A, Erdmann I, Theiling K, Rother M, Ring J, Cevc G, Abeck D,. Improved risk-benefit ratio for topical triamcinolone acetonide in Transfersome in comparison with equipotent cream and ointment: A randomized controlled trial. Br J Dermatol 2003; 149 (3): 611-619. (Pubitemid 37281596)
144. Bungener L, Serre K, Bijl L, Leserman L, Wilschut J, Daemen T, Machy P,. Virosome-mediated delivery of protein antigens to dendritic cells. Vaccine 2002; 20 (17-18): 2287-2295. (Pubitemid 34497039)
145. Mastrobattista E, Crommelin DJ, Wilschut J, Storm G,. Targeted liposomes for delivery of protein-based drugs into the cytoplasm of tumor cells. J Liposome Res 2002; 12 (1-2): 57-65. (Pubitemid 34846957)
146. Matlin KS, Reggio H, Helenius A, Simons K,. Infectious entry pathway of influenza virus in a canine kidney cell line. J Cell Biol 1981; 91 (3 Pt 1): 601-613. (Pubitemid 12211148)
147. Felnerova D, Viret JF, Gluck R, Moser C,. Liposomes and virosomes as delivery systems for antigens, nucleic acids and drugs. Curr Opin Biotechnol 2004; 15 (6): 518-529. (Pubitemid 39551004)
148. Gluck R, Burri KG, Metcalfe I,. Adjuvant and antigen delivery properties of virosomes. Curr Drug Deliv 2005; 2 (4): 395-400. (Pubitemid 41277771)
149. Kaneda Y,. Virosome: A novel vector to enable multi-modal strategies for cancer therapy. Adv Drug Deliv Rev 2011. DOI: 10.1016/j.addr.2011.03.007.
150. Sprott GD, Tolson DL, Patel GB,. Archaeosomes as novel antigen delivery systems. FEMS Microbiol Lett 1997; 154 (1): 17-22. (Pubitemid 27376731)
151. Patel GB, Sprott GD,. Archaeobacterial ether lipid liposomes (archaeosomes) as novel vaccine and drug delivery systems. Crit Rev Biotechnol 1999; 19 (4): 317-357. (Pubitemid 30036089)
152. Krishnan L, Sprott GD,. Archaeosome adjuvants: Immunological capabilities and mechanism(s) of action. Vaccine 2008; 26 (17): 2043-2055.
153. Dragicevic-Curic N, Scheglmann D, Albrecht V, Fahr A,. Development of liposomes containing ethanol for skin delivery of temoporfin: Characterization and in vitro penetration studies. Colloids Surf B Biointerfaces 2009; 74 (1): 114-122.
154. Touitou E, Dayan N, Bergelson L, Godin B, Eliaz M,. Ethosomes-Novel vesicular carriers for enhanced delivery: Characterization and skin penetration properties. J Control Release 2000; 65 (3): 403-418. (Pubitemid 30122942)
155. Dayan N, Touitou E,. Carriers for skin delivery of trihexyphenidyl HCl: Ethosomes vs. liposomes. Biomaterials 2000; 21 (18): 1879-1885. (Pubitemid 30398506)
156. Fang YP, Tsai YH, Wu PC, Huang YB,. Comparison of 5-aminolevulinic acid-encapsulated liposome versus ethosome for skin delivery for photodynamic therapy. Int J Pharm 2008; 356 (1-2): 144-152.
157. Fang YP, Huang YB, Wu PC, Tsai YH,. Topical delivery of 5-aminolevulinic acid-encapsulated ethosomes in a hyperproliferative skin animal model using the CLSM technique to evaluate the penetration behavior. Eur J Pharm Biopharm 2009; 73 (3): 391-398.
158. Dragicevic-Curic N, Grafe S, Albrecht V, Fahr A,. Topical application of temoporfin-loaded invasomes for photodynamic therapy of subcutaneously implanted
159. Sengupta S, Eavarone D, Capila I, Zhao G, Watson N, Kiziltepe T, Sasisekharan R,. Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system. Nature 2005; 436 (7050): 568-572. (Pubitemid 41112931)
160. Spring B, Mai Z, Rai P, Chang S, Hasan T,. Theranostic nanocells for simultaneous imaging and photodynamic therapy of pancreatic cancer. Proc SPIE 2010; 7551: 755104. DOI: 10.1117/12.843725.
161. Lovell JF, Jin CS, Huynh E, Jin H, Kim C, Rubinstein JL, Chan WC, Cao W, Wang LV, Zheng G,. Porphysome nanovesicles generated by porphyrin bilayers for use as multimodal biophotonic contrast agents. Nat Mater 2011; 10 (4): 324-3332.
162. Bangham AD, Standish MM, Watkins JC,. Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol 1965; 13 (1): 238-252.
163. Celli JP, Spring BQ, Rizvi I, Evans CL, Samkoe KS, Verma S, Pogue BW, Hasan T,. Imaging and photodynamic therapy: Mechanisms, monitoring, and optimization. Chem Rev 2010; 110 (5): 2795-2838.